clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Fibrosis D005355 23 associated lipids
Tooth Discoloration D014075 7 associated lipids
Sinusitis D012852 9 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Cross Infection D003428 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Dermatomycoses D003881 17 associated lipids
Fever D005334 35 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Bronchial Spasm D001986 18 associated lipids
Hyperlipidemias D006949 73 associated lipids
Bronchitis D001991 6 associated lipids
Shock, Septic D012772 11 associated lipids
Iritis D007500 2 associated lipids
Syphilis D013587 6 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Hearing Disorders D006311 10 associated lipids
Duodenitis D004382 4 associated lipids
Metaplasia D008679 7 associated lipids
Foot Diseases D005534 4 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Radiation Injuries D011832 14 associated lipids
Urticaria D014581 13 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
HIV Seropositivity D006679 15 associated lipids
Endophthalmitis D009877 12 associated lipids
Leprosy D007918 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Paronychia D010304 3 associated lipids
Dyspnea D004417 10 associated lipids
Pyelonephritis D011704 5 associated lipids
Angina Pectoris D000787 27 associated lipids
Klebsiella Infections D007710 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Çekin AH et al. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. 2017 Turk J Gastroenterol pmid:28007678
AvÅŸar E et al. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients. 2013 Turk J Gastroenterol pmid:24254262
Ozdil B et al. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication. 2010 Turk J Gastroenterol pmid:20533108
Özden A et al. Effectiveness of different treatment regimens in helicobacter pylori eradication: ten-year experience of a single institution. 2010 Turk J Gastroenterol pmid:20931423
YaÅŸar B et al. Efficacy of probiotics in Helicobacter pylori eradication therapy. 2010 Turk J Gastroenterol pmid:20931422
Sezgin O et al. Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey. 2008 Turk J Gastroenterol pmid:19115151
Tümgör G et al. Comparison of standard and standard plus vitamin E therapy for Helicobacter pylori eradications in children. 2014 Turk J Gastroenterol pmid:25910378
Çiftci İH et al. Comparison of FISH, RFLP and agar dilution methods for testing clarithromycin resistance of Helicobacter pylori. 2014 Turk J Gastroenterol pmid:25910373
Oztürk K et al. Diagnosis of helicobacter pylori infection. 2014 Turk J Gastroenterol pmid:25141328
Erçin CN et al. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. 2010 Turk J Gastroenterol pmid:20533106
Zhen-Hua Z et al. Characterization of 23S rRNA gene mutation in primary and secondary clarithromycin-resistant Helicobacter pylori strains from East China. 2013 Turk J Gastroenterol pmid:23794337
Baysal B et al. Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients. 2015 Turk J Gastroenterol pmid:25698264
Uygun A et al. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. 2004 Turk J Gastroenterol pmid:16249974
Yakut M et al. Sequential therapy for Helicobacter pylori eradication. 2010 Turk J Gastroenterol pmid:20931421
Güliter S et al. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori? 2005 Turk J Gastroenterol pmid:16252185
Cinar K et al. The effect of Helicobacter pylori eradication in patients with functional dyspepsia: assessment of different diagnostic tests. 2004 Turk J Gastroenterol pmid:15492914
Aydin A et al. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases. 2005 Turk J Gastroenterol pmid:16547848
AladaÄŸ M et al. Comparison of pantoprazole- vs. omeprazole- based triple therapy regimens in the treatment of Helicobacter pylori infection and duodenal ulcer healing in a Turkish population. 2005 Turk J Gastroenterol pmid:16547858
Sarkeshikian SS et al. Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. 2013 Turk J Gastroenterol pmid:23794338
Sezgin O et al. Bismuth-based therapies for the first step eradication of Helicobacter pylori. 2006 Turk J Gastroenterol pmid:16830288
Demirci H et al. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. 2015 Turk J Gastroenterol pmid:26510082
Bilgin M et al. Acute coronary syndrome secondary to clarithromycin: the first case and review of the literature. 2014 Turk Kardiyol Dern Ars pmid:25080953
DoÄŸru D et al. Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. 2009 Sep-Oct Turk. J. Pediatr. pmid:20112595
Yildirim I et al. Comparison of the effect of benzathine penicillin G, clarithromycin, cefprozil and amoxicillin/clavulanate on the bacteriological response and throat flora in group A beta hemolytic streptococcal tonsillopharyngitis. 2008 Mar-Apr Turk. J. Pediatr. pmid:18664074
Tezer H et al. Mycoplasma pneumoniae-associated transverse myelitis with unexpected rapid response to macrolide therapy: a case report. 2008 Nov-Dec Turk. J. Pediatr. pmid:19227425
Çağan-Appak Y et al. Clarithromycin resistance and 23S rRNA gene point mutations of Helicobacter pylori infection in children. 2016 Turk. J. Pediatr. pmid:28276208
Schouenborg P [Clarithromycin]. 1996 Ugeskr. Laeg. pmid:8686028
Schmidt BJ and Hermansen MN [Late debut of neonatal pneumonia caused by Chlamydia trachomatis]. 2013 Ugeskr. Laeg. pmid:23428270
Petersen AM et al. [Resistance of Helicobacter pylori to clarithomycin]. 1998 Ugeskr. Laeg. pmid:9627511
Buch T and Andersen SE [Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval]. 2015 Ugeskr. Laeg. pmid:26471025
Velho PE et al. Severe anemia, panserositis, and cryptogenic hepatitis in an HIV patient infected with Bartonella henselae. 2007 Nov-Dec Ultrastruct Pathol pmid:18098054
Yoshida K et al. Chlamydia trachomatis infection in the semen of asymptomatic infertile men: detection of the antigen by in situ hybridization. 1994 Urol. Int. pmid:7855940
NeÄ­mark AI et al. [Efficacy of low-intensity laser radiation and antibacterial therapy in the treatment of chronic prostatitis in the presence of sexually transmitted infections]. 2007 May-Jun Urologiia pmid:17724830
Gao M et al. The effects of transrectal radiofrequency hyperthermia on patients with chronic prostatitis and the changes of MDA, NO, SOD, and Zn levels in pretreatment and posttreatment. 2012 Urology pmid:22100490
El-Garem Y et al. Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men. 2014 Urology pmid:25432826
Lange JN et al. Sensitivity of human strains of Oxalobacter formigenes to commonly prescribed antibiotics. 2012 Urology pmid:22656407
Lee CK et al. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. 1999 Vaccine pmid:10195786
Rendi-Wagner P et al. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. 2009 Vaccine pmid:19393711
Robinson JG Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. 2009 Vasc Health Risk Manag pmid:19436666
Kones R Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. 2010 Vasc Health Risk Manag pmid:20859545
Bronander KA and Bloch MJ Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. 2007 Vasc Health Risk Manag pmid:17580728
Wolbrette D et al. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. 2010 Vasc Health Risk Manag pmid:20730068
Falk JA et al. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. 2010 Vasc Health Risk Manag pmid:20479949
Edmonds M The treatment of diabetic foot infections: focus on ertapenem. 2009 Vasc Health Risk Manag pmid:19997576
Laks T et al. Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study. 2008 Vasc Health Risk Manag pmid:19337553
[Experience with treatment of chronic polypoid rhinosinusitis using low doses of clarithromycin in the postoperative period]. 2012 Vestn. Otorinolaringol. pmid:22678641
Bobacheva TIu [The treatment of chronic polypous rhinosinusitis in the postoperative period with low doses of clarithromycin]. 2012 Vestn. Otorinolaringol. pmid:23011378
Murai A et al. Mastitis caused by Mycobacterium kansasii infection in a dog. 2013 Vet Clin Pathol pmid:23808608
Hylton PK et al. Intracellular success: cytologic findings in an ulcerated submandibular mass from a cat. 2006 Vet Clin Pathol pmid:16967424
Muller MG et al. Acinetobacter baumannii in Localised Cutaneous Mycobacteriosis in Falcons. 2010 Vet Med Int pmid:20871867